{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:00:01Z","timestamp":1790614801722,"version":"4.1.0"},"reference-count":79,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T00:00:00Z","timestamp":1659484800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Faculty of Medicine, Ramathibodi Hospital, Mahidol University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Molecules"],"abstract":"<jats:p>Differentiated thyroid cancer (DTC), arising from thyroid follicular epithelial cells, is the most common type of thyroid cancer. Despite the well-known utilization of radioiodine treatment in DTC, i.e., iodine-131, radioiodine imaging in DTC is typically performed with iodine-123 and iodine-131, with the current hybrid scanner performing single photon emission tomography\/computed tomography (SPECT\/CT). Positron emission tomography\/computed tomography (PET\/CT) provides superior visualization and quantification of functions at the molecular level; thus, lesion assessment can be improved compared to that of SPECT\/CT. Various types of cancer, including radioiodine-refractory DTC, can be detected by 2-[18F]fluoro-2-deoxy-D-glucose ([18F]FDG), the most well-known and widely used PET radiopharmaceutical. Several other PET radiopharmaceuticals have been developed, although some are limited in availability despite their potential clinical utilizations. This article aims to summarize PET radiopharmaceuticals in DTC, focusing on molecular pathways and applications.<\/jats:p>","DOI":"10.3390\/molecules27154936","type":"journal-article","created":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T23:33:01Z","timestamp":1659569581000},"page":"4936","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Positron Emission Tomography Radiopharmaceuticals in Differentiated Thyroid Cancer"],"prefix":"10.3390","volume":"27","author":[{"given":"Chaninart","family":"Sakulpisuti","sequence":"first","affiliation":[{"name":"Division of Nuclear Medicine, Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Putthiporn","family":"Charoenphun","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wichana","family":"Chamroonrat","sequence":"additional","affiliation":[{"name":"Division of Nuclear Medicine, Department of Diagnostic and Therapeutic Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok 10400, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/thy.2015.0020","article-title":"2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer","volume":"26","author":"Haugen","year":"2016","journal-title":"Thyroid"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dunlap, Q., and Davies, L. (2021). Differentiated Thyroid Cancer Incidence. Surgery of the Thyroid and Parathyroid Glands, Elsevier.","DOI":"10.1016\/B978-0-323-66127-0.00017-X"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ecl.2018.10.002","article-title":"Evolving Understanding of the Epidemiology of Thyroid Cancer","volume":"48","author":"Seib","year":"2019","journal-title":"Endocrinol. Metab. Clin. N. Am."},{"key":"ref_4","unstructured":"(2022, June 11). SEER*Explorer Surveillance Research Program, National Cancer Institute, Available online: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/application.html."},{"key":"ref_5","unstructured":"O\u2019Malley, J.P., and Ziessman, H.A. (2019). Nuclear Medicine and Molecular Imaging: The Requisites, Elsevier Inc. [5th ed.]."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1148\/rg.332125051","article-title":"SPECT\/CT Evaluation of Unusual Physiologic Radioiodine Biodistributions: Pearls and Pitfalls in Image Interpretation","volume":"33","author":"Glazer","year":"2013","journal-title":"RadioGraphics"},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Cascini, G.L., Niccoli Asabella, A., Notaristefano, A., Restuccia, A., Ferrari, C., Rubini, D., Altini, C., and Rubini, G. (2014). 124Iodine: A Longer-Life Positron Emitter Isotope\u2014New Opportunities in Molecular Imaging. BioMed Res. Int., 2014.","DOI":"10.1155\/2014\/672094"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40336-016-0186-7","article-title":"The Role of Iodine-124 Positron Emission Tomography in Molecular Imaging","volume":"4","author":"Mahajan","year":"2016","journal-title":"Clin. Transl. Imaging"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.diii.2021.04.004","article-title":"PET\/CT in the Management of Differentiated Thyroid Cancer","volume":"102","author":"Zampella","year":"2021","journal-title":"Diagn. Interv. Imaging"},{"key":"ref_10","first-page":"15N","article-title":"SNMMI Procedure Standard\/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version","volume":"63","author":"Avram","year":"2022","journal-title":"J. Nucl. Med."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Klain, M., Zampella, E., Nappi, C., Nicolai, E., Ambrosio, R., Califaretti, E., Lamartina, L., Schlumberger, M., Deandreis, D., and Salvatore, D. (2021). Advances in Functional Imaging of Differentiated Thyroid Cancer. Cancers, 13.","DOI":"10.3390\/cancers13194748"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/RLU.0000000000003505","article-title":"Optimal Time for 124I PET\/CT Imaging in Metastatic Differentiated Thyroid Cancer","volume":"46","author":"Wu","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.2967\/jnumed.115.169649","article-title":"High Level of Agreement between Pretherapeutic 124I PET and Intratherapeutic 131I Imaging in Detecting Iodine-Positive Thyroid Cancer Metastases","volume":"57","author":"Ruhlmann","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1089\/thy.2009.0430","article-title":"124I Positron Emission Tomography Versus 131I Planar Imaging in the Identification of Residual Thyroid Tissue and\/or Metastasis in Patients Who Have Well-Differentiated Thyroid Cancer","volume":"20","author":"Moreau","year":"2010","journal-title":"Thyroid"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1089\/thy.2013.0713","article-title":"Do Negative 124I Pretherapy Positron Emission Tomography Scans in Patients with Elevated Serum Thyroglobulin Levels Predict Negative 131I Posttherapy Scans?","volume":"24","author":"Khorjekar","year":"2014","journal-title":"Thyroid"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s00259-007-0660-6","article-title":"The Diagnostic Value of 124I-PET in Patients with Differentiated Thyroid Cancer","volume":"35","author":"Phan","year":"2008","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_17","first-page":"536","article-title":"The Effectiveness of 124I PET\/CT in Patients with Differentiated Thyroid Cancer","volume":"53","author":"Capoccetti","year":"2009","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00259-012-2331-5","article-title":"124I PET\/CT in the Pretherapeutic Staging of Differentiated Thyroid Carcinoma: Comparison with Posttherapy 131I SPECT\/CT","volume":"40","author":"Halders","year":"2013","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1089\/thy.2015.0482","article-title":"124I PET\/CT in Patients with Differentiated Thyroid Cancer: Clinical and Quantitative Image Analysis","volume":"26","author":"Gulec","year":"2016","journal-title":"Thyroid"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"701","DOI":"10.2967\/jnumed.115.168138","article-title":"124I PET\/CT to Predict the Outcome of Blind 131I Treatment in Patients with Biochemical Recurrence of Differentiated Thyroid Cancer: Results of a Multicenter Diagnostic Cohort Study (THYROPET)","volume":"57","author":"Kist","year":"2016","journal-title":"J. Nucl. Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/RLU.0000000000003499","article-title":"124I-PET\/CT\u2013Guided Diagnosis and Personalized Treatment of Metastatic Papillary Thyroid Cancer to the Pancreas","volume":"46","author":"Wong","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"235","DOI":"10.23736\/S1824-4785.19.03201-1","article-title":"The Role of 124I PET\/CT Lesion Dosimetry in Differentiated Thyroid Cancer","volume":"63","author":"Weber","year":"2019","journal-title":"Q. J. Nucl. Med. Mol. Imaging"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/cen.13306","article-title":"Utility of I-124 PET\/CT in Identifying Radioiodine Avid Lesions in Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis","volume":"86","author":"Santhanam","year":"2017","journal-title":"Clin. Endocrinol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1021\/bc500475e","article-title":"Fluorine-18 Radiochemistry, Labeling Strategies and Synthetic Routes","volume":"26","author":"Jacobson","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.2967\/jnumed.117.192252","article-title":"18F-Tetrafluoroborate, a PET Probe for Imaging Sodium\/Iodide Symporter Expression: Whole-Body Biodistribution, Safety, and Radiation Dosimetry in Thyroid Cancer Patients","volume":"58","author":"Brothwood","year":"2017","journal-title":"J. Nucl. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Khoshnevisan, A., Jauregui-Osoro, M., Shaw, K., Torres, J.B., Young, J.D., Ramakrishnan, N.K., Jackson, A., Smith, G.E., Gee, A.D., and Blower, P.J. (2016). [18F]Tetrafluoroborate as a PET Tracer for the Sodium\/Iodide Symporter: The Importance of Specific Activity. EJNMMI Res., 6.","DOI":"10.1186\/s13550-016-0188-5"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1007\/s00259-020-04727-9","article-title":"Incremental Diagnostic Value of [18F]Tetrafluoroborate PET-CT Compared to [131I]Iodine Scintigraphy in Recurrent Differentiated Thyroid Cancer","volume":"47","author":"Dittmann","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1097\/RLU.0000000000001977","article-title":"Initial Clinical Investigation of [18F]Tetrafluoroborate PET\/CT in Comparison to [124I]Iodine PET\/CT for Imaging Thyroid Cancer","volume":"43","author":"Samnick","year":"2018","journal-title":"Clin. Nucl. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Yu, S. (2006). Review of 18F-FDG Synthesis and Quality Control. Biomed. Imaging Interv. J., 2.","DOI":"10.2349\/biij.2.4.e57"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1159\/000346303","article-title":"[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography\/Computed Tomography Imaging in Oncology: Initial Staging and Evaluation of Cancer Therapy","volume":"22","author":"Pauwels","year":"2013","journal-title":"Med. Princ. Pract."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1148\/rg.242025724","article-title":"An Introduction to PET-CT Imaging","volume":"24","author":"Kapoor","year":"2004","journal-title":"RadioGraphics"},{"key":"ref_32","first-page":"1468","article-title":"Fluorine-18-FDG and Iodine-131-Iodide Uptake in Thyroid Cancer","volume":"37","author":"Feine","year":"1996","journal-title":"J. Nucl. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1007\/s40336-013-0025-z","article-title":"Cellular and Molecular Basis for Thyroid Cancer Imaging in Nuclear Medicine","volume":"1","author":"Bongiovanni","year":"2013","journal-title":"Clin. Transl. Imaging"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Heydarzadeh, S., Moshtaghie, A.A., Daneshpoor, M., and Hedayati, M. (2020). Regulators of Glucose Uptake in Thyroid Cancer Cell Lines. Cell Commun. Signal., 18.","DOI":"10.1186\/s12964-020-00586-x"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.endinu.2020.02.007","article-title":"Role of 18F-FDG-PET\/CT in Patients with Differentiated Thyroid Cancer with Biochemical Incomplete or Indeterminate Response to Treatment","volume":"67","author":"Abelleira","year":"2020","journal-title":"Endocrinol. Diabetes Nutr."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1530\/EJE-19-0261","article-title":"Diagnostic Performance of 18F-FDG-PET\/CT in DTC Patients with Thyroglobulin Elevation and Negative Iodine Scintigraphy: A Meta-Analysis","volume":"181","author":"Qichang","year":"2019","journal-title":"Eur. J. Endocrinol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/hed.23881","article-title":"Accuracy of Positron Emission Tomography and Positron Emission Tomography-CT in the Detection of Differentiated Thyroid Cancer Recurrence with Negative 131I Whole-Body Scan Results: A Meta-Analysis: PET and PET-CT in the Detection of Recurrent Differentiated Thyroid Cancer","volume":"38","author":"Caetano","year":"2016","journal-title":"Head Neck"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1007\/s00259-015-3195-2","article-title":"[18F]FDG PET\/CT Outperforms [18F]FDG PET\/MRI in Differentiated Thyroid Cancer","volume":"43","author":"Vrachimis","year":"2016","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Wang, H., Dai, H., Li, Q., Shen, G., Shi, L., and Tian, R. (2021). Investigating 18F-FDG PET\/CT Parameters as Prognostic Markers for Differentiated Thyroid Cancer: A Systematic Review. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.648658"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Albano, D., Dondi, F., Mazzoletti, A., Bellini, P., Rodella, C., and Bertagna, F. (2021). Prognostic Role of 2-[18F]FDG PET\/CT Metabolic Volume Parameters in Patients Affected by Differentiated Thyroid Carcinoma with High Thyroglobulin Level, Negative 131I WBS and Positive 2-[18F]-FDG PET\/CT. Diagnostics, 11.","DOI":"10.3390\/diagnostics11122189"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1097\/MNM.0000000000000480","article-title":"The Role of 18F-FDG PET\/CT in the Follow-up of Well-Differentiated Thyroid Cancer with Negative Thyroglobulin but Positive and\/or Elevated Antithyroglobulin Antibody","volume":"37","author":"Liu","year":"2016","journal-title":"Nucl. Med. Commun."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1530\/ERC-17-0341","article-title":"Diagnostic Performance of PET in Thyroid Cancer with Elevated Anti-Tg Ab","volume":"25","author":"Kim","year":"2018","journal-title":"Endocr.-Relat. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1097\/RLU.0b013e318286827b","article-title":"Correlation of 18F-FDG PET\/CT Findings with Histopathological Results in Differentiated Thyroid Cancer Patients Who Have Increased Thyroglobulin or Antithyroglobulin Antibody Levels and Negative 131I Whole-Body Scan Results","volume":"38","author":"Ozkan","year":"2013","journal-title":"Clin. Nucl. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/RLU.0b013e31825ae77b","article-title":"The Additive Clinical Value of 18F-FDG PET\/CT in Defining the Recurrence of Disease in Patients with Differentiated Thyroid Cancer Who Have Isolated Increased Antithyroglobulin Antibody Levels","volume":"37","author":"Ozkan","year":"2012","journal-title":"Clin. Nucl. Med."},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"de Leijer, J.F., Metman, M.J.H., van der Hoorn, A., Brouwers, A.H., Kruijff, S., van Hemel, B.M., Links, T.P., and Westerlaan, H.E. (2021). Focal Thyroid Incidentalomas on 18F-FDG PET\/CT: A Systematic Review and Meta-Analysis on Prevalence, Risk of Malignancy and Inconclusive Fine Needle Aspiration. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.723394"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1007\/s00259-014-2774-y","article-title":"18F-FDG Uptake as a Prognostic Variable in Primary Differentiated Thyroid Cancer Incidentally Detected by PET\/CT: A Multicentre Study","volume":"41","author":"Piccardo","year":"2014","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejmp.2018.05.024","article-title":"PET Textural Features Stability and Pattern Discrimination Power for Radiomics Analysis: An \u201cAd-Hoc\u201d Phantoms Study","volume":"50","author":"Presotto","year":"2018","journal-title":"Phys. Med."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Gherghe, M., Lazar, A.M., Mutuleanu, M.-D., Stanciu, A.E., and Martin, S. (2022). Radiomics Analysis of [18F]FDG PET\/CT Thyroid Incidentalomas: How Can It Improve Patients\u2019 Clinical Management? A Systematic Review from the Literature. Diagnostics, 12.","DOI":"10.3390\/diagnostics12020471"},{"key":"ref_49","first-page":"3536","article-title":"PSMA Expression in Differentiated Thyroid Cancer: Association with Radioiodine, 18FDG Uptake, and Patient Outcome","volume":"106","author":"Ciappuccini","year":"2021","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1148\/radiol.2021202771","article-title":"Prostate-Specific Membrane Antigen PET in Prostate Cancer","volume":"299","author":"Salavati","year":"2021","journal-title":"Radiology"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2174\/1874471009666161028150654","article-title":"Gallium-68 in Medical Imaging","volume":"9","author":"Martiniova","year":"2016","journal-title":"Curr. Radiopharm."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Hennrich, U., and Eder, M. (2021). [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer. Pharmaceuticals, 14.","DOI":"10.3390\/ph14080713"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gourni, E., and Henriksen, G. (2017). Metal-Based PSMA Radioligands. Molecules, 22.","DOI":"10.3390\/molecules22040523"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Basuli, F., Phelps, T.E., Zhang, X., Woodroofe, C.C., Roy, J., Choyke, P.L., Swenson, R.E., and Jagoda, E.M. (2022). Fluorine-18 Labeled Urea-Based Ligands Targeting Prostate-Specific Membrane Antigen (PSMA) with Increased Tumor and Decreased Renal Uptake. Pharmaceuticals, 15.","DOI":"10.3390\/ph15050597"},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Bychkov, A., Vutrapongwatana, U., Tepmongkol, S., and Keelawat, S. (2017). PSMA Expression by Microvasculature of Thyroid Tumors\u2014Potential Implications for PSMA Theranostics. Sci. Rep., 7.","DOI":"10.1038\/s41598-017-05481-z"},{"key":"ref_56","first-page":"1511","article-title":"Thyroid Cancer Detected on 68Ga-PMSA PET\/CT","volume":"71","author":"Usmani","year":"2021","journal-title":"J. Pak. Med. Assoc."},{"key":"ref_57","first-page":"145","article-title":"More than the Prostate: Intrapancreatic Accessory Spleen and Papillary Thyroid Cancer Detected with 18F-PSMA PET\/CT","volume":"21","author":"Singh","year":"2018","journal-title":"Hell. J. Nucl. Med."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lawhn-Heath, C., Yom, S.S., Liu, C., Villanueva-Meyer, J.E., Aslam, M., Smith, R., Narwal, M., Juarez, R., Behr, S.C., and Pampaloni, M.H. (2020). Gallium-68 Prostate-Specific Membrane Antigen ([68Ga]Ga-PSMA-11) PET for Imaging of Thyroid Cancer: A Feasibility Study. EJNMMI Res., 10.","DOI":"10.1186\/s13550-020-00720-3"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pitalua-Cortes, Q., Garc\u00eda-Perez, F.O., Vargas-Ahumada, J., Gonzalez-Rueda, S., Gomez-Argumosa, E., Ignacio-Alvarez, E., Soldevilla-Gallardo, I., and Torres-Agredo, L. (2021). Head-to-Head Comparison of 68Ga-PSMA-11 and 131I in the Follow-Up of Well-Differentiated Metastatic Thyroid Cancer: A New Potential Theragnostic Agent. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.794759"},{"key":"ref_60","first-page":"S42","article-title":"68Ga-PSMA Uptake in a Radioiodine-Refractory Metastatic Differentiated Thyroid Cancer Patient","volume":"41","author":"Arslan","year":"2021","journal-title":"Rev. Esp. Med. Nucl. Imagen Mol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"e406","DOI":"10.1097\/RLU.0000000000003655","article-title":"Prostate-Specific Membrane Antigen Expression in Patients with Differentiated Thyroid Cancer with Thyroglobulin Elevation and Negative Iodine Scintigraphy Using 68Ga-PSMA-HBED-CC PET\/CT","volume":"46","author":"Verma","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"De Vries, L.H., Lodewijk, L., Braat, A.J.A.T., Krijger, G.C., Valk, G.D., Lam, M.G.E.H., Borel Rinkes, I.H.M., Vriens, M.R., and de Keizer, B. (2020). 68Ga-PSMA PET\/CT in Radioactive Iodine-Refractory Differentiated Thyroid Cancer and First Treatment Results with 177Lu-PSMA-617. EJNMMI Res., 10.","DOI":"10.1186\/s13550-020-0610-x"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Lewis, J.S., Windhorst, A.D., and Zeglis, B.M. (2019). Radiopharmaceutical Chemistry, Springer International Publishing.","DOI":"10.1007\/978-3-319-98947-1"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.2217\/fon.14.139","article-title":"PET Tracers for Somatostatin Receptor Imaging of Neuroendocrine Tumors: Current Status and Review of the Literature","volume":"10","author":"Johnbeck","year":"2014","journal-title":"Future Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-0029-1243636","article-title":"Somatostatin Receptor Subtype Expression in Human Thyroid Tumours","volume":"42","author":"Klagge","year":"2010","journal-title":"Horm. Metab. Res."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"290","DOI":"10.14310\/horm.2002.1357","article-title":"Somatostatin Receptor Expression in Non-Medullary Thyroid Carcinomas","volume":"11","author":"Koletsa","year":"2012","journal-title":"Hormones"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1097\/MNM.0b013e328364eaab","article-title":"Evaluation and Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET\/CT Imaging in Well-Differentiated Thyroid Cancer","volume":"34","author":"Ocak","year":"2013","journal-title":"Nucl. Med. Commun."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Bodei, L., Mueller-Brand, J., Baum, R.P., Pavel, M.E., H\u00f6rsch, D., O\u2019Dorisio, M.S., O\u2019Dorisio, T.M., Howe, J.R., Cremonesi, M., and Kwekkeboom, D.J. (2014). Erratum to: The Joint IAEA, EANM, and SNMMI Practical Guidance on Peptide Receptor Radionuclide Therapy (PRRNT) in Neuroendocrine Tumours. Eur. J. Nucl. Med. Mol. Imaging, 41.","DOI":"10.1007\/s00259-013-2454-3"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa1607427","article-title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","volume":"376","author":"Strosberg","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1097\/RLU.0000000000003110","article-title":"Peptide Receptor Radionuclide Therapy in Patients with Differentiated Thyroid Cancer: A Meta-Analysis","volume":"45","author":"Lee","year":"2020","journal-title":"Clin. Nucl. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"68Ga-FAPI PET\/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"68Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J. Nucl. Med."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Lindner, T., Giesel, F.L., Kratochwil, C., and Serfling, S.E. (2021). Radioligands Targeting Fibroblast Activation Protein (FAP). Cancers, 13.","DOI":"10.3390\/cancers13225744"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Huang, R., Pu, Y., Huang, S., Yang, C., Yang, F., Pu, Y., Li, J., Chen, L., and Huang, Y. (2022). FAPI-PET\/CT in Cancer Imaging: A Potential Novel Molecule of the Century. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.854658"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Fu, H., Wu, J., Huang, J., Sun, L., Wu, H., Guo, W., Qiu, S., and Chen, H. (2022). 68Ga Fibroblast Activation Protein Inhibitor PET\/CT in the Detection of Metastatic Thyroid Cancer: Comparison with 18F-FDG PET\/CT. Radiology, 304.","DOI":"10.1148\/radiol.212430"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1007\/s12149-022-01742-8","article-title":"68Ga-DOTA-FAPI-04 PET\/CT Imaging in Radioiodine-Refractory Differentiated Thyroid Cancer (RR-DTC) Patients","volume":"36","author":"Chen","year":"2022","journal-title":"Ann. Nucl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1007\/s12020-021-02668-3","article-title":"Comparison of 68Ga-FAPI and 18F-FDG PET\/CT in Metastases of Papillary Thyroid Carcinoma","volume":"73","author":"Wu","year":"2021","journal-title":"Endocrine"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1097\/RLU.0000000000003730","article-title":"68Ga-FAPI PET\/CT Versus 18F-FDG PET\/CT for Detecting Metastatic Lesions in a Case of Radioiodine-Refractory Differentiated Thyroid Cancer","volume":"46","author":"Fu","year":"2021","journal-title":"Clin. Nucl. Med."},{"key":"ref_79","first-page":"65","article-title":"Novel Fibroblast Activation Protein Inhibitor-Based Targeted Theranostics for Radioiodine-Refractory Differentiated Thyroid Cancer Patients: A Pilot Study","volume":"32","author":"Ballal","year":"2021","journal-title":"Thyroid"}],"container-title":["Molecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/15\/4936\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:01:42Z","timestamp":1760140902000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1420-3049\/27\/15\/4936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,3]]},"references-count":79,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["molecules27154936"],"URL":"https:\/\/doi.org\/10.3390\/molecules27154936","relation":{},"ISSN":["1420-3049"],"issn-type":[{"value":"1420-3049","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,3]]}}}